BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Z, Lin C, Suo C, Zhao R, Jin L, Zhang T, Chen X. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism 2021;127:154955. [PMID: 34915036 DOI: 10.1016/j.metabol.2021.154955] [Reference Citation Analysis]
2 Rajak S, Gupta P, Anjum B, Raza S, Tewari A, Ghosh S, Tripathi M, Singh BK, Sinha RA. Role of AKR1B10 and AKR1B8 in the pathogenesis of non-alcoholic steatohepatitis (NASH) in mouse. Biochim Biophys Acta Mol Basis Dis 2021;:166319. [PMID: 34954342 DOI: 10.1016/j.bbadis.2021.166319] [Reference Citation Analysis]
3 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
4 Vuille-lessard É, Lange N, Riebensahm C, Dufour J, Berzigotti A. Dietary Interventions in Liver Diseases: Focus on MAFLD and Cirrhosis. Curr Hepatology Rep 2021;20:61-76. [DOI: 10.1007/s11901-021-00563-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pastor CM, Vilgrain V. Steatosis Alters the Activity of Hepatocyte Membrane Transporters in Obese Rats. Cells 2021;10:2733. [PMID: 34685713 DOI: 10.3390/cells10102733] [Reference Citation Analysis]
6 Alharthi J, Eslam M. Metabolic associated fatty liver disease (MAFLD): a milestone in the history of fatty liver disease. Hepatobiliary Surg Nutr 2021;10:696-8. [PMID: 34760977 DOI: 10.21037/hbsn-21-269] [Reference Citation Analysis]
7 Han H, Jiang Y, Wang M, Melaku M, Liu L, Zhao Y, Everaert N, Yi B, Zhang H. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-18. [PMID: 34404276 DOI: 10.1080/10408398.2021.1966738] [Reference Citation Analysis]
8 Abuja PM, Zatloukal K, Denk H. Priming, Triggering, Adaptation and Senescence (PTAS): A Hypothesis for a Common Damage Mechanism of Steatohepatitis. Int J Mol Sci 2021;22:12545. [PMID: 34830427 DOI: 10.3390/ijms222212545] [Reference Citation Analysis]
9 Xia Y, Caputo M, Cansby E, Anand SK, Sütt S, Henricsson M, Porosk R, Marschall HU, Blüher M, Mahlapuu M. STE20-type kinase TAOK3 regulates hepatic lipid partitioning. Mol Metab 2021;54:101353. [PMID: 34634521 DOI: 10.1016/j.molmet.2021.101353] [Reference Citation Analysis]
10 Xue R, Su L, Lai S, Wang Y, Zhao D, Fan J, Chen W, Hylemon PB, Zhou H. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease. Cells 2021;10:2806. [PMID: 34831031 DOI: 10.3390/cells10112806] [Reference Citation Analysis]